Home > News > BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
February 3rd, 2004
BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
BioSante Pharmaceuticals, Inc. reiterated today its Cooperative Research and Development Agreement with the U.S. Army's Medical Research Institute of Infectious Diseases for the development of a needle-free vaccine against ricin, a poisonous substance thought to have been detected in a U.S. Senate mailroom this week. BioSante has provided BioVant(TM), its proprietary nanoparticulate-based vaccine adjuvant and delivery system, and the Army has provided recombinant antigens to be used in potential vaccines against various bioterrorism agents.
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013